Welcome to our dedicated page for Novocure news (Ticker: NVCR), a resource for investors and traders seeking the latest updates and insights on Novocure stock.
Novocure Limited (NASDAQ: NVCR) is a global oncology company centered on Tumor Treating Fields (TTFields) therapy, and its news flow reflects both commercial performance and clinical development across aggressive solid tumors. Company press releases emphasize TTFields-based products such as Optune Gio for glioblastoma and Optune Lua for metastatic non-small cell lung cancer (mNSCLC) and mesothelioma-related indications.
Investors following NVCR news will find regular updates on quarterly and annual net revenues, active patient counts on TTFields therapy, and geographic contributions from the United States and international markets. Novocure frequently reports metrics for Optune Gio and Optune Lua prescriptions, active patients by indication and region, and recognized revenue from specific products and partnerships.
News coverage also highlights clinical and regulatory milestones. Novocure issues announcements on Phase 2 and Phase 3 trials such as PANOVA-3 and PANOVA-4 in pancreatic cancer, TRIDENT in newly diagnosed glioblastoma and METIS in brain metastases from NSCLC. Releases describe key outcomes, including when pivotal trials meet primary endpoints or support regulatory submissions. The company also reports on premarket approval (PMA) applications to the U.S. Food and Drug Administration for new TTFields indications and approvals from regulators such as Japan’s Ministry of Health, Labour and Welfare for Optune Lua.
Another recurring theme in NVCR news is participation in major healthcare and oncology conferences, including the J.P. Morgan Healthcare Conference, Jefferies Global Healthcare Conference, Piper Sandler Healthcare Conference, EANO, ESMO and ASTRO. These events often feature Novocure management presentations, investor meetings and scientific data on TTFields therapy.
For readers tracking NVCR, this news page aggregates company announcements on financial results, product approvals, clinical trial data, leadership changes and scientific presentations, offering a consolidated view of developments around Novocure’s TTFields-based oncology platform.
Novocure (NASDAQ: NVCR) announced the election of Dr. Allyson J. Ocean to its Board of Directors. Dr. Ocean is a prominent medical oncologist with expertise in gastrointestinal oncology, currently serving at Weill Cornell Medicine. Her role is expected to enhance Novocure’s mission to extend survival in aggressive cancers through innovative therapies. She is also co-founder of a non-profit focused on pancreatic cancer treatment access. Novocure is known for its Tumor Treating Fields, a revolutionary therapy approved for conditions such as glioblastoma and malignant pleural mesothelioma, with ongoing studies in various cancers.
Novocure (NASDAQ: NVCR) reported its financial results for Q4 and the full year 2022, achieving net revenues of $538 million for the year and $128 million for the quarter. The pivotal LUNAR study in non-small cell lung cancer successfully met its primary and secondary overall survival endpoints. Novocure completed enrollment for the pivotal PANOVA-3 study in pancreatic cancer and is nearing completion of the METIS study in brain metastases. Despite a 4% revenue decline in Q4, the company reported a 78% gross margin and held $969 million in cash as of December 31, 2022.
Novocure (NASDAQ: NVCR) has completed patient enrollment in the pivotal PANOVA-3 study, assessing the efficacy of Tumor Treating Fields (TTFields) combined with nab-paclitaxel and gemcitabine in treating locally advanced pancreatic cancer. With approximately 43,000 annual diagnoses in the U.S. and a stagnant five-year survival rate of just 10%, this study represents a significant milestone. The trial will follow patients for at least 18 months, focusing on overall survival as the primary endpoint and several secondary endpoints. The results, expected in 2024, could offer hope for improving survival rates in this challenging cancer type.
Novocure (NASDAQ: NVCR) announced key organizational changes effective January 17, 2023, aiming for growth. Pritesh Shah will become Chief Growth Officer, overseeing product strategy and market access. Ely Benaim will leave as Chief Medical Officer, with interim leadership transitioning to Piet Hinoul. Uri Weinberg becomes Chief Innovation Officer, while Moshe Giladi steps into Chief Science Officer. CEO Asaf Danziger noted the recent positive developments in pivotal studies, signaling a transformative period for the company. Novocure focuses on expanding its Tumor Treating Fields therapy for various cancers.
Novocure (NASDAQ: NVCR) reported preliminary net revenues of
Novocure's LUNAR study achieved its primary endpoint, showing significant improvement in overall survival for stage 4 NSCLC patients treated with Tumor Treating Fields (TTFields) alongside standard therapies.
The study revealed that TTFields combined with immune checkpoint inhibitors (ICI) and docetaxel led to better survival rates compared to standard treatments alone. Novocure plans to submit a Premarket Approval application to the FDA and a CE Mark application in the second half of 2023. This marks a pivotal moment in treating late-stage lung cancer, addressing a critical unmet need.
Novocure (NASDAQ: NVCR) will participate in the 41st Annual J. P. Morgan Healthcare Conference on January 10-11, 2023. Executive Chairman William Doyle will speak at 7:30 a.m. PST on January 10, 2023, addressing analysts' questions. Additionally, Doyle and CFO Ashley Cordova will hold one-on-one meetings with investors. A live audio webcast of the presentation will be available on Novocure's Investor Relations page, along with a replay for at least 14 days post-event. Novocure focuses on extending survival in aggressive cancers through its innovative Tumor Treating Fields therapy.
Health Canada has approved Optune for glioblastoma, marking the first such treatment in Canada in over 12 years. Novocure aims to secure reimbursement for Optune to enhance accessibility for patients. Optune utilizes Tumor Treating Fields to disrupt cancer cell division, with 25,000 patients treated globally. Clinical trials show improved overall survival of 20.9 months with Optune and temozolomide, versus 16 months with temozolomide alone. The approval is seen as a significant advancement for GBM treatment in Canada.
Novocure (NASDAQ: NVCR) announced its participation in the 34th Annual Piper Sandler Healthcare Conference on December 1, 2022. Executive Chairman William Doyle and CFO Ashley Cordova will engage in a fireside chat at 9:30 a.m. EST, alongside one-on-one investor meetings. A live webcast will be available on Novocure's Investor Relations page, with replay access for 14 days. Novocure, based in Switzerland, focuses on innovative cancer therapies, primarily using Tumor Treating Fields, with ongoing clinical studies in various cancer types.
Novocure (NASDAQ: NVCR) presented 25 abstracts on Tumor Treating Fields (TTFields) at the SNO 2022 Annual Meeting from Nov. 16-20, highlighting significant advancements in glioblastoma treatment.
Key findings include an analysis showing TTFields therapy improved median overall survival in patients with glioblastoma, extending it to 17.6 months versus 13.1 months for those not treated. The largest safety dataset of over 23,000 high-grade glioma patients demonstrated TTFields' high tolerability.